Gland Pharma Share Price (GLAND)
Check the latest share price of Gland Pharma, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Gland Pharma Stock Performance
Get live Gland Pharma share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,629.9Day's Price Range₹1,694.552 Week's Low
52 Week's High
₹1,277.852-Week Price Range₹2,220.95
| Returns % | |
| 1 Month Return | + 15.64 % |
| 3 Month Return | + 8.54 % |
| 1 Year Return | -8.46 % |
| 3 Year Return | -37.17 % |
| 5 Year Return | -7.14 % |
| Market Stats | |
| Previous Close | ₹1,669.40 |
| Open | ₹1,630.00 |
| Volume | 88.07K |
| Upper Circuit | ₹2,003.20 |
| Lower Circuit | ₹1,335.60 |
Gland Pharma Fundamentals & Key Indicators
Check Gland Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹27,838.89 Cr
Return on Equity (ROE)
12.31
PE Ratio (TTM)
39.85
Return on capital employed (ROCE)
16.65
Industry PE ratio
57.39
Beta (LTM)
0.69
P/B Ratio
3.37
Dividend Yield
1.09
PEG Ratio
-8.86
Quarterly Earnings Growth YOY
-3.06
EPS (TTM)
46.9
Sector
Pharmaceuticals
Book Value
529.65
Technical Analysis
Bullish
View Technical Analysis
How to invest in Gland Pharma?
Investing in Gland Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Gland Pharma or GLAND on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Gland Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Gland Pharma with just a few clicks!
Gland Pharma Stock's Interest Amongst Investors
Gland Pharma Valuation
Track how Gland Pharma P/E has moved over time to understand its valuation trends.
Gland Pharma in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (39.85x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (67.14x)
August 12, 2021
Today’s Price to Earnings Ratio: 39.85x
Gland Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Gland Pharma.
based on 12 analysts
41.67%
Buy
8.33%
Hold
50.00%
Sell
50% of analysts recommend a 'HOLD' rating for Gland Pharma. Average target price of ₹1677.67
Source: S&P Global Market Intelligence
Gland Pharma Share Price Target
Get share price movements and forecasts by analysts on Gland Pharma.
Gland Pharma price forecast by 12 analysts
Downside of-0.71%
High
₹3120
Target
₹1677.67
Low
₹1162
Gland Pharma target price ₹1677.67, a slight downside of -0.71% compared to current price of ₹1689.7. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma revenue growth forecast
Expected growth rate Q1, FY2027:26.26%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma EPS growth forecast
EPS estimate Q1, FY2027:50.41%
Forecast
Actual
Source: S&P Global Market Intelligence
Gland Pharma Financial Results
Get the annual and quarterly financial summary of Gland Pharma, including revenue, profit, loss and more.
Indices Featuring Gland Pharma Stock
Check stock indices that include Gland Pharma.
Gland Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Gland Pharma.
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit fell -3.06% since last year same period to ₹186.54Cr in the Q4 2024-2025. On a quarterly growth basis, Gland Pharma Ltd has generated -8.87% fall in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Gland Pharma Ltd has declared dividend of ₹20 - translating a dividend yield of 1.18%.
Read More about Dividends
Gland Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Gland Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | 0.00 | |
| Foreign Institutions | 6.9% | 0.00 | |
| Mutual Funds | 31.16% | 0.00 | |
| Retail Investors | 7.99% | 0.00 | |
| Others | 2.11% | 0.00 |
Gland Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Gland Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 27,838.89 | -1.43% | 0.50 | 772 | 5,664 | |
| HOLD | 1,76,987.90 | 37.1% | 0.50 | 1,600 | 7,845 | |
| BUY | 1,10,074.44 | 32.82% | 0.67 | 1,656 | 10,727 | |
| BUY | 42,669.32 | -1.66% | 0.58 | 1,297 | 14,755 | |
| BUY | 1,21,573.55 | 26.77% | 0.50 | 4,155 | 25,774 |
Gland Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Gland Pharma.
Gland Pharma Ltd Gains for Fifth Consecutive Session - 10 Jun, 2025
Gland Pharma Ltd rose 0.15% to Rs 1650.9, marking its fifth consecutive gain. Despite a 11.98% decline over the past year, the stock has gained 15.44% in the last month. The Nifty Pharma index also saw a 3.79% increase in the same period.Gland Pharma Secures USFDA Approval for Injection - 04 Jun, 2025
Gland Pharma has received USFDA approval for its Angiotensin II Acetate Injection, which is bioequivalent to Giapreza. The company reported a decline in Q4 FY25 net profit and revenue but announced a final dividend of ₹18 per share.Gland Pharma's Growth Prospects and Market Opportunities - 27 May, 2025
Gland Pharma, a leading B2B generic injectable company, has a robust pipeline with a $6.5 billion US market opportunity. The company is expected to benefit from a turnaround in its French CDMO operations and potential in-licensing deals for GLP-1 contracts, which could drive significant growth in FY26/FY27.Gland Pharma Faces Challenges but Shows Potential Upside - 21 May, 2025
Gland Pharma's Q4 results showed a decline in profit and sales, yet shares rose due to stable margins and a dividend announcement. Analysts maintain cautious optimism, with Elara projecting a 23% upside despite execution issues. Kotak forecasts mid-teen growth for FY2026, highlighting ongoing challenges in the US market and Cenexi operations.Gland Pharma Reports Q4 Decline and Strategic Focus - 20 May, 2025
Gland Pharma's Q4 results show a 3.1% profit decline to ₹186.5 crore, driven by lower U.S. sales. The company proposes an ₹18 dividend and aims for growth in emerging markets amid operational challenges.Gland Pharma Q4 Preview Shows Positive Outlook - 19 May, 2025
Gland Pharma is expected to report stable Q4 results, with a projected 0.9% revenue increase to Rs 1,551.73 crore. Strong US business momentum and new launches may offset seasonal weaknesses, while net profit is anticipated to rise to Rs 233.36 crore. Concerns about tariff risks and margin pressure remain.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 1.44K Cr → 1.46K Cr (in ₹), with an average increase of 1.8% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 5.04% to 6.90% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 131.1% return, outperforming this stock by 168.2%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.83% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 53.8%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 8.33% to 7.99% in Mar 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 204.69 Cr → 186.54 Cr (in ₹), with an average decrease of 8.9% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 32.37% to 31.16% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 years, GLAND stock has moved down by -37.2%
About Gland Pharma
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Revenue: ₹1,424.91Cr as on March 2025 (Q4 FY25)
Net Profit: ₹186.54Cr as on March 2025 (Q4 FY25)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma Ltd |
| Industry | Pharmaceuticals |
| CEO | Yiu Kwan Stanley Lau |
| E-voting on shares | Click here to vote |
Mutual Funds that own Gland Pharma
Check out the Mutual Funds with significant holdings in Gland Pharma.
FAQs
What is Gland Pharma share price today?
Gland Pharma share price today stands at ₹1689.7, Open: ₹1630, Previous Close: ₹1669.4, High: ₹1694.5, Low: ₹1629.9, 52 Week High: ₹2220.95, 52 Week Low: ₹1277.8.
What is today's traded volume of Gland Pharma?
Today's traded volume of Gland Pharma is 88.07K. Which means that 88.07K shares of Gland Pharma were bought and sold on the stock market during today's trading session.
What is Gland Pharma's market cap today?
Today's market capitalisation of Gland Pharma is ₹27,838.89 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Gland Pharma?
Gland Pharma’s 52 week high is ₹2220.95 and 52 week low is ₹1277.8. The current share price of Gland Pharma is ₹1689.7, which is -23.92% down from its 52 week high and 32.24% up from its 52 week low.